PDL BioPharma pioneered the humanization of monoclonal antibodies
and, by so doing, enabled the discovery
of a new generation of targeted treatments for cancer and immunologic diseases.

CEO Newsletter

Company Presentations & Events

News Releases

09/01/10

PDL BioPharma Provides Third Quarter 2010 Revenue Guidance of Approximately $86 Million and Update to its Correspondence With Genentech

08/13/10

PDL BioPharma Receives Letter from Genentech Relating to European Patents